Evidence map›Paper›PMID 37876208›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Grade of Primary Cutaneous Leiomyosarcoma Dictates Risk for Metastatic Spread and Disease-Specific Mortality.

Michael J Carr, James Sun, William A Adams, Michelle M Dugan, Syeda M H Naqvi, Youngchul Kim, Jane L Messina, Ricardo J Gonzalez, Jonathan S Zager, John E Mullinax

Open access · goldAbstract read
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Michael J CarrDepartment of Sarcoma, Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0001-6233-4004
James SunDepartment of Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
William A AdamsUniversity of South Florida Morsani College of Medicine, Tampa, FL, USA.
Michelle M DuganDepartment of Sarcoma, Moffitt Cancer Center, Tampa, FL, USA.
Syeda M H NaqviDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
Youngchul KimDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
Jane L MessinaCutaneous Oncology Department, Moffitt Cancer Center, Tampa, FL, USA.
Ricardo J GonzalezDepartment of Sarcoma, Moffitt Cancer Center, Tampa, FL, USA.
Jonathan S ZagerDepartment of Sarcoma, Moffitt Cancer Center, Tampa, FL, USA.
John E MullinaxDepartment of Sarcoma, Moffitt Cancer Center, Tampa, FL, USA.
University of South Florida · USMoffitt Cancer Center · USUniversity Hospitals of Cleveland · USUniversity of Louisville · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

BACKGROUND AND

objectivesPrimary cutaneous leiomyosarcoma (cLMS), a rare, typically intradermal tumor, has previously been reported to exhibit an indolent course of disease with zero-to-low risk of local recurrence or distant metastasis. This study seeks to evaluate recurrence and survival of cLMS patients through study of its clinicopathologic and treatment characteristics.

methodsAll patients included underwent resection of primary cLMS at this institution between 2006 and 2019. A retrospective cohort study analysis of clinicopathologic characteristics, treatment, recurrence, and overall survival was performed. Data was assessed through descriptive statistics and outcome measures assessed by Cox proportional models and log-rank tests.

resultsEighty-eight patients with cLMS were evaluated. The majority were men (n = 68, 77%) and Caucasian (n = 85, 97%), with median age at diagnosis of 66 years (range 20-96). 65% of tumors were located on the extremities, with a median size of 1.3 cm (range .3-15). Assessment revealed low (n = 41, 47%), intermediate (n = 29, 33%), and high (n = 18, 20%) grade tumors, demonstrating extension into subcutaneous tissue in 38/60 (60%), with 3 patients exhibiting extension into muscle (3%). All underwent resection as primary treatment with median 1 cm margins (range .5-2). With median follow-up of 27.5 months (IQR 8-51; range 1-131), no low-grade cases had recurrence or death while there was a recurrence rate of 19.1% (9/47) and death rate of 8.5% (4/47) in intermediate- to high-grade cases.

conclusionsPrimary tumor resection of cLMS provides excellent local control for low-grade tumors as no low-grade cases experienced recurrence. For patients with intermediate- to high-grade tumors, there is potential for local recurrence, distant metastasis, and death, and therefore surveillance following treatment is encouraged.

Indexed as

LeiomyosarcomaSkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsRetrospective StudiesYoung Adultcutaneous leiomyosarcomagrademetastasissarcoma

Identifiers

PMID37876208
PMCPMC10605670
OpenAlexW4387931043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.